Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (5466)	2/1/1998 2:10:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

There was article on use of a glass , pressed against the rash. If spots do not appear to go away this could indicate meningitis. Appeared on Dec 22 as part of longer article on treatment of 100 cases of meningitis in 1997 at hospital engaged in ".... an international trial of a treatment that appears to stop septic shock killing the most seriously ill patients. They are treating patients with a protein synthesised from white blood cells. 'IT BLOCKS THE CASCADE OF TOXIC SHOCK THAT SETS IN WHEN PATIENTS HAVE SEPTICAEMIA" , said the doctor who is helping to conduct the trial. Article does not mention Xoma but I am sure the co is Xoma. Got the article early last week. Tried to get additional info and struck out. Wanted total number enrolled in trial and total number of deaths. Delayed post because I did not want to spook the potential source of more info. Xoma was made aware of the article, by same person that made me ware of it. It's on the web. Posted now because I have given up on enhancing the info.and will not be able to post until late Wed. It stll is not 100% clear that the comments on the "benefits" are based on present trial or what has been revealed by P II trials. Article also states that about 60% of patients get both infla. of the brain & blood poisoning which made me believe there would be value to knowing total deaths.